Biotech Plus Therapeutics Halts Stock Offering Plans Amid Market Conditions
Filing Impact
Filing Sentiment
Form Type
RW
Rhea-AI Filing Summary
Plus Therapeutics has submitted a request to withdraw its Registration Statement on Form S-3 (File No. 333-286393) that was initially filed on April 4, 2025, and amended on April 23, 2025.
Key points of the withdrawal request:
- The company has decided not to proceed with the registration of the contemplated resale of securities
- Confirms that no securities were sold under this Registration Statement
- Requests that all fees paid to the SEC be credited to the company's account for future registration statement filings under Rule 457(p)
- The withdrawal request is made pursuant to Rule 477(a) under the Securities Act of 1933
This withdrawal indicates a change in the company's capital raising or securities registration strategy, though specific reasons for the withdrawal were not disclosed.
Positive
- None.
Negative
- Company withdraws Form S-3 registration statement for resale of securities, indicating a change in capital raising strategy or market conditions
FAQ
Why did PSTV withdraw its S-3 registration statement in June 2025?
PSTV withdrew its S-3 registration statement (File No. 333-286393) because the company determined not to proceed with the contemplated resale of securities at this time. The company confirmed that no securities were sold pursuant to the Registration Statement.
When was PSTV's S-3 registration statement originally filed?
PSTV's S-3 registration statement was initially filed with the SEC on April 4, 2025, and was subsequently amended on April 23, 2025.
What happens to the filing fees PSTV paid for the withdrawn S-3 registration?
According to the withdrawal request, PSTV requested that all fees paid to the SEC in connection with the filing be credited to the company's account under Rule 457(p), to be offset against filing fees for any future registration statements the company may file.
Who is the current CEO of PSTV as of the June 2025 filing?
Marc H. Hedrick, MD serves as the President & Chief Executive Officer of PSTV, as evidenced by his signature on the withdrawal request.